CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Upgraded by StockNews.com

CRISPR Therapeutics (NASDAQ:CRSP) was upgraded by StockNews.com to a “sell” rating in a report released on Friday.

CRSP has been the subject of a number of other reports. Citigroup dropped their price target on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Chardan Capital dropped their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, February 13th. Truist Financial increased their price target on CRISPR Therapeutics from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, February 12th. Stifel Nicolaus lowered their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research report on Thursday, February 13th. Finally, Barclays raised their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $73.11.

CRISPR Therapeutics Stock Performance

Shares of CRSP stock opened at $41.22 on Friday. The stock’s fifty day moving average price is $43.09 and its two-hundred day moving average price is $45.37. The company has a market cap of $3.54 billion, a PE ratio of -9.43 and a beta of 1.76. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $73.09.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts predict that CRISPR Therapeutics will post -5.16 EPS for the current fiscal year.

Insider Activity

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 18,360 shares of CRISPR Therapeutics stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the transaction, the chief executive officer now owns 171,613 shares in the company, valued at approximately $9,473,037.60. The trade was a 9.66 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director John Greene purchased 7,000 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were bought at an average price of $44.85 per share, with a total value of $313,950.00. Following the purchase, the director now directly owns 7,000 shares in the company, valued at approximately $313,950. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 32,381 shares of company stock worth $1,608,243 in the last three months. Company insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Wood Tarver Financial Group LLC acquired a new position in CRISPR Therapeutics during the 4th quarter valued at about $30,000. Ameriflex Group Inc. bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $36,000. Highline Wealth Partners LLC bought a new position in shares of CRISPR Therapeutics during the 4th quarter worth approximately $39,000. Western Pacific Wealth Management LP lifted its position in shares of CRISPR Therapeutics by 100.0% during the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after buying an additional 500 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB bought a new position in shares of CRISPR Therapeutics during the 3rd quarter worth approximately $40,000. Institutional investors and hedge funds own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.